Evidence map›Paper›PMID 35514898›Full record

ReviewRSC advances2020

Two decades of recent advances of Ugi reactions: synthetic and pharmaceutical applications.

Manar Ahmed Fouad, Hamida Abdel-Hamid, Mohammed Salah Ayoup

Abstract readReview
In one paragraph

Review in RSC advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed.

  1. Review
  2. Multicomponent Reactions for the Synthesis of Oxazepines.Topics in current chemistry (Cham) · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Covalent Proximity Inducers.Chemical reviews · 2025
    Review
  9. Article
  10. CspACS catalysis · 2024
    Article
  11. Article
  12. Biosynthesis of isonitrile lipopeptides.Current opinion in chemical biology · 2024
    Review
  13. Non-symmetric stapling of native peptides.Nature reviews. Chemistry · 2024
    Review
  14. Diastereoselective ZnClMolecules (Basel, Switzerland) · 2024
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Manar Ahmed FouadDepartment of Chemistry, Faculty of Science, Alexandria University Alexandria 21321 Egypt mohammedsalahayoup@gmail.com mohamed.salah@alexu.edu.eg.ORCID https://orcid.org/0000-0001-9128-9118
Hamida Abdel-HamidDepartment of Chemistry, Faculty of Science, Alexandria University Alexandria 21321 Egypt mohammedsalahayoup@gmail.com mohamed.salah@alexu.edu.eg.
Mohammed Salah AyoupDepartment of Chemistry, Faculty of Science, Alexandria University Alexandria 21321 Egypt mohammedsalahayoup@gmail.com mohamed.salah@alexu.edu.eg.ORCID https://orcid.org/0000-0001-6715-5478

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multicomponent reactions (MCRs) are powerful synthetic tools in which more than two starting materials couple with each other to form multi-functionalized compounds in a one-pot process, the so-called "tandem", "domino" or "cascade" reaction, or utilizing an additional step without changing the solvent, the so-called a sequential-addition procedure, to limit the number of synthetic steps, while increasing the complexity and the molecular diversity, which are highly step-economical reactions. The Ugi reaction, one of the most common multicomponent reactions, has recently fascinated chemists with the high diversity brought by its four- or three-component-based isonitrile. The Ugi reaction has been introduced in organic synthesis as a novel, efficient and useful tool for the preparation of libraries of multifunctional peptides, natural products, and heterocyclic compounds with stereochemistry control. In this review, we highlight the recent advances of the Ugi reaction in the last two decades from 2000-2019, mainly in the synthesis of linear or cyclic peptides, heterocyclic compounds with versatile ring sizes, and natural products, as well as the enantioselective Ugi reactions. Meanwhile, the applications of these compounds in pharmaceutical trials are also discussed.

Identifiers

PMID35514898
PMCPMC9058431

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.